NDA 202667 · Thea Pharma
Cosopt Pf
Dorzolamide Hydrochloride, Timolol Maleate · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Feb 1, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
82
19 Phase 3, 2 recruiting
FAERS reports
2,587
782 serious, 320 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 13, 2026.
COSOPT® PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT® administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14.1) ]. • COSOPT PF is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor inhibitor, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. • The IOP-lowering of COSOPT twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. ( 1 )
Mechanism: COSOPT PF is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- COSOPT PF · DORZOLAMIDE HYDROCHLORIDE EQ 2% BASE; TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT2
Clinical trials
Interventional ClinicalTrials.gov studies with "Dorzolamide" as an intervention, any sponsor and status, largest first.
- MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00449956 · 474 participants · Start Mar 12, 2007 · Primary completion Feb 16, 2008
Drug: dorzolamide hydrochloride (+) timolol maleate; Comparator: timolol maleate and 1 more · For: Glaucoma
- A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00314171 · 437 participants · Start Oct 2005 · Primary completion Aug 2007
Drug: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension; Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT) · For: Open-angle Glaucoma; Ocular Hypertension
- Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle GlaucomaPivotal-lookingNot yet recruiting
Ache Laboratorios Farmaceuticos S.A.Industry
NCT07617532 · 336 participants (planned) · Start Jun 2026 · Primary completion Mar 2028
Drug: Product DNN.31.19.026; COSOPT® · For: Ocular Hypertension; Primary Open Angle Glaucoma
- Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00108017 · 330 participants · Start Apr 2005 · Primary completion Jul 2006
Drug: MK0507A, dorzolamide hydrochloride (+) timolol maleate; Comparator: timolol maleate and 2 more · For: Glaucoma; Ocular Hypertension
- A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00333125 · 319 participants · Start Apr 2006 · Primary completion Feb 2007
Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav); Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt) · For: Glaucoma; Ocular Hypertension
- The International Collaborative Exfoliation Syndrome Treatment StudyPivotal-lookingStatus unknown
The New York Eye & Ear InfirmaryAcademic, hospital or other
NCT00804115 · 277 participants · Start Aug 2000 · Primary completion Sep 2007
Drug: Latanoprost with Pilocarpine vs Timolol or Cosopt · For: Exfoliation Syndrome; Glaucoma; Ocular Hypertension
Sites: New York, New York
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ GlaucomaPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00140049 · 238 participants · Start Jul 2005
Drug: Xalacom; Cosopt · For: Glaucoma, Open Angle; Ocular Hypertension
Sites: Caen, France; Clermont-Ferrand, France; Lyon, France · 25 sites in all
- Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic SolutionPivotal-lookingCompleted
Alcon, a Novartis CompanyIndustry
NCT02325518 · 218 participants · Start Dec 2014 · Primary completion Dec 2015
Drug: Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension; Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
Sites: Tokyo, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation513
- ocular hyperaemia453
- eye pruritus308
- drug ineffective256
- eye pain227
- death210
- eye swelling195
- vision blurred139
- lacrimation increased130
- hypersensitivity128
- dyspnoea101
- glaucoma97
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 12 |
| 2010 | 30 |
| 2011 | 28 |
| 2012 | 17 |
| 2013 | 101 |
| 2014 | 27 |
| 2015 | 7 |
| 2016 | 86 |
| 2017 | 181 |
| 2018 | 187 |
| 2019 | 463 |
| 2020 | 601 |
| 2021 | 283 |
| 2022 | 196 |
| 2023 | 171 |
| 2024 | 62 |
| 2025 | 70 |
| 2026 | 60 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cosopt PF (Dorzolamide/Timolol/PF)
2024 spending
$4.5M
Beneficiaries
3,125
12,769 claims
Per beneficiary
$1,445
$3.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $4,250,622 |
| 2024 | $4,516,110 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Topical dorzolamide for macular holes: A randomised, double-blind, placebo-controlled trial.
Lee YM, Bahrami B, Baranage D, et al. · Clin Exp Ophthalmol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- [Approaches for improvement of ocular surface condition in primary open-angle glaucoma].
Yanchenko SV, Sakhnov SN, Malyshev AV, et al. · Vestn Oftalmol 2024 · Randomized Controlled Trial, English Abstract
- Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid.
Jóhannesson G, Moya-Ortega MD, Ásgrímsdóttir GM, et al. · Acta Ophthalmol 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A comparison of dorzolamide-timolol combination versus the concomitant drugs.
Choudhri S, Wand M, Shields MB · Am J Ophthalmol 2000 · Clinical Trial, Comparative Study
- Efficacy of Topical Carbonic Anhydrase Inhibitors in Reducing Duration of Chronic Central Serous Chorioretinopathy.
Liew G, Ho IV, Ong S, et al. · Transl Vis Sci Technol 2020 · Controlled Clinical Trial
Sponsor: Thea Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.